Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Stock Skyrocketed Today

By Joe Tenebruso - Mar 19, 2021 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's experimental cancer treatment demonstrated promising results in a clinical trial.

What happened 

Shares of Clovis Oncology (CLVS -5.29%) soared 48% on Friday after the biopharmaceutical company announced positive findings from its phase 3 study for its ovarian cancer drug, Rubraca. 

So what 

Data from the clinical trial showed Rubraca to significantly improve progression-free survival (PFS) compared to standard-of-care chemotherapy among patients with advanced, relapsed ovarian cancer and a specific gene variant, known as a deleterious BRCA mutation.

The study enrolled 349 women in multiple countries. The median PFS for the patients treated with Rubraca was 7.4 months, compared to 5.7 months for those who received chemotherapy.

A person is pointing to an upwardly sloping line.

Clovis Oncology's stock price surged on Friday. Image source: Getty Images.

Clovis Oncology said the adverse events observed among the study's participants, such as anemia and fatigue, were consistent with the known safety profiles of Rubraca and chemotherapy.

"We remain committed to expanding treatment options for patients living with cancer and are pleased to share these data with physicians and their patients to help improve outcomes for women with ovarian cancer," Clovis Oncology CEO Patrick Mahaffy said in a press release.

Now what

More than 21,000 women will be diagnosed with ovarian cancer in the U.S. alone this year, according to the American Cancer Society. Worse still, nearly 14,000 of these women are likely to die from the disease. Rubraca could potentially give doctors another tool to combat this far-to-often deadly form of cancer.

Thus, should it receive regulatory approval, demand for Rubraca would likely be strong -- which is why investors bid up Clovis Oncology's stock price so sharply today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$0.74 (-5.29%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.